Hebrew
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
carcinosarcoma/עייפות
הקישור נשמר בלוח
11 תוצאות
[Case of pulmonary carcinosarcoma and a summary of 17 cases reported in Japan].
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
The patient was a 69-year-old man who complained of dyspnea and severe general fatigue. Chest CT showed a large tumor (6 x 5 cm) in the left S3 together with left pleural effusion. Despite pleurodesis and chemotherapy, he died 1.5 months after admission. At autopsy, a final diagnosis of pulmonary
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma.
METHODS
This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
BACKGROUND
The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or persistent uterine carcinosarcoma (UCS). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Exploratory
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
This multi-institutional phase II trial assessed the activity and toxicity of imatinib mesylate and explored c-Kit and platelet-derived growth factor receptor (PDGFR)-beta in recurrent or persistent uterine carcinosarcoma.
METHODS
Women with measurable uterine carcinosarcoma, who had a
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
The aim of this multi-institutional non randomized phase II trial was to determine the efficacy and safety of single agent aflibercept (VEGF Trap), a recombinant fusion protein that blocks multiple vascular endothelial growth factor isoforms, in women with gynecologic soft tissue
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
To evaluate the efficacy and adverse events of thalidomide in previously-treated, measurable, persistent or recurrent carcinosarcoma of the uterus, and to explore associations between angiogenic markers with patient demographics and clinical outcome.
METHODS
Eligible, consenting patients
Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Endometrial cancers have high rates of phosphoinositide 3-kinase (PI3K) pathway alterations. MK-2206 is an allosteric inhibitor of AKT, an effector kinase of PI3K signals. We hypothesized patients with tumors harboring PIK3CA mutations would be more likely to benefit from MK-2206 than those without
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
Treatment options remain limited for women with relapsed/metastatic endometrial cancer (EC). Angiogenesis is one of the major components of tumor progression and thus an attractive target. The aim of this phase II trial was to assess the efficacy and tolerability of sunitinib, an oral
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas.
METHODS
All patients with sarcoma or carcinosarcoma of gynecologic origin and documented recurrence or persistence of disease after appropriate surgery, radiation
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Purpose Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor. This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients. Design A 3 + 3 dose escalation design was used followed by the
המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע
- עובד ב 55 שפות
- מרפא צמחי מרפא מגובה על ידי מדע
- זיהוי עשבי תיבול על ידי דימוי
- מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
- קרא פרסומים מדעיים הקשורים לחיפוש שלך
- חפש עשבי מרפא על פי השפעותיהם
- ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים
הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם
